KURA · Kura Oncology, Inc. · Stock research

Current Thesis

The binary already fired. Ziftomenib (Komzifti) won FDA approval on 2025-11-13 for relapsed/refractory NPM1-mutant AML the first once-daily oral menin inhibitor and the stock ran from a $5.45 pre-approval low (2025-08-11) to a $12.49 high the day after (2025-11-14). Eight months on it is consolidating near that high (~$11.44, 2026-07-10) while the actual trade the Street underwrites frontline expansion worth the $24-28 price targets sits gated behind a Phase 3 (KOMET-017) that does not read out until 2028. That is a de-risked, price-target-cheap biotech in a two-year catalyst gap, not an accelerating narrative a momentum book gets paid to chase early. The next observable read is the second launch quarter on 2026-08-06.

Bullish and bearish views on Kura Oncology, Inc.

The model's bull view on Kura Oncology, Inc. (KURA), in brief: Komzifti FDA-approved 2025-11-13 for R/R NPM1-mutant AML, ahead of the 2025-11-30 PDUFA; first full launch quarter (Q1 2026) posted $5.8M net product revenue real, ramping commercial sales rather than clinical-stage promise. The bear view: The re-rating event is in the past. Approval fired eight months ago, and the launch is early and small: $5.8M product revenue, $73.3M net loss, collaboration revenue $12.5M (down from $14.1M YoY) in Q1 2026; 2026 collaboration guide is only $45-55M. Two-year catalyst desert: the… Both cases follow in full.

Bull Case

• Komzifti FDA-approved 2025-11-13 for R/R NPM1-mutant AML, ahead of the 2025-11-30 PDUFA; first full launch quarter (Q1 2026) posted $5.8M net product revenue real, ramping commercial sales rather than clinical-stage promise.
• Frontline is the value driver, and the data is strong: KOMET-007 (ziftomenib + 7+3 intensive chemo, 99 patients at 600mg) showed 90-96% composite remission, 94% 12-month survival in the NPM1-m cohort, and 83% MRD-negativity among NPM1-m responders one of the largest menin-inhibitor-plus-chemo frontline datasets, presented at EHA 2026 (announced 2026-06-11).
• Safety differentiation versus Syndax's revumenib (Revuforj): ziftomenib carries no QTc-prolongation/Torsades boxed warning, which matters as the class pushes into frontline chemo combinations.
• Funded to the next binary: $580.8M cash and investments at 2026-03-31 plus ~$180M anticipated Kyowa Kirin payments fund the ziftomenib AML program through the first KOMET-017 Phase 3 top-line (2028); no near-term dilution overhang.
• Kyowa Kirin collaboration (Nov 2024): $330M upfront, up to $420M near-term milestones, up to $1.161B total including a solid-tumor opt-in, 50/50 US profit share with Kura booking US sales; a $30M milestone already paid on KOMET-017 first-patient dosing.
• Sell-side well above spot: Citizens reiterated Market Outperform, $24 target (2026-06-15); consensus median ~$28 (range $16-76) against ~$11.44.

Bear Case

• The re-rating event is in the past. Approval fired eight months ago, and the launch is early and small: $5.8M product revenue, $73.3M net loss, collaboration revenue $12.5M (down from $14.1M YoY) in Q1 2026; 2026 collaboration guide is only $45-55M.
• Two-year catalyst desert: the transformative Phase 3 KOMET-017 top-line is not expected until 2028, leaving no binary to force a re-rate and plenty of room to bleed.
• Crowded class: Syndax's Revuforj reached market first and covers both KMT2A-r and R/R NPM1; J&J's bleximenib, Sumitomo's enzomenib and Servier's S243249 are advancing. Frontline share is contested, and Kura lost the initial R/R race.
• The approved R/R NPM1 monotherapy is a narrow niche; the $24-28 targets require frontline standard-of-care adoption that has not been demonstrated commercially.
• Burn is real: cash fell ~$86M in the quarter ($667.2M at 2025-12-31 to $580.8M at 2026-03-31); runway assumes Kyowa milestones land on schedule.

Setup & Price Structure

• ~$11.44 (2026-07-10). 52-week range $5.45 (2025-08-11) to $12.49 (2025-11-14, post-approval). The name has doubled off the pre-approval low and now trades ~8% below its high.
• Range-bound roughly $10-12.5 through H1 2026 near highs but flat and non-parabolic. There is no momentum acceleration and no fresh breakout to lean on.
• Narrative velocity is absent: sell-side already carries $24-28 targets, so the "in before the upgrade" edge this playbook exists to capture is gone. Strength here is a stall, not a signal.
• The setup to size up would be a decisive breakout and weekly close above the $12.49 52-week high on a launch inflection or renewed frontline momentum. Absent that, fresh interest is a small starter at most; the cleaner stance is to stand aside until the range resolves.

Catalyst Calendar (next 30 days)

• 2026-08-06 (consensus earnings calendar): Q2 2026 results the second full Komzifti launch quarter and the first clean read on script trajectory and reimbursement traction. Soft but the only dated event in the window; a momentum entry should respect the print risk as it approaches within three trading days.
• No FDA/PDUFA action, label expansion, or Phase 3 readout scheduled in the window. The next true binary (KOMET-017 top-line) is ~2028.

What Would Change Our Mind

• A weekly close below $9.50 breaks the post-approval consolidation base and loses the rising 200-day, signaling the slow launch is overwhelming the frontline optionality and the range is resolving lower.
• Secondary conditions: Q2 Komzifti product revenue flat or down versus Q1's $5.8M (launch stalling out of the gate), or the menin-inhibitor theme flipping to SATURATED as revumenib and bleximenib capture frontline share ahead of KOMET-017.
• The bearish caution itself is invalidated by a weekly close above $12.49 on expanding volume paired with a launch or frontline-data inflection, which would flip this from a catalyst-gap wait into a momentum long.

Correlation Notes

• Closest comp and direct competitor: Syndax (SNDX), the other pure-play menin inhibitor; the two trade on class read-through and can diverge on head-to-head frontline share data.
• Class read-through: J&J (bleximenib), Sumitomo Pharma (enzomenib) and Servier pipeline entrants move sentiment on the whole menin-inhibitor thesis.
• Broadly, KURA tracks small-cap biotech beta (XBI) and AML/hematology-oncology risk appetite.